Noelle Sunstrom and the Potential Growth for NeuClone

Season 3, Episode 6,   May 24, 2020, 11:00 AM

Looking through its robust pipeline of biosimilars, it’s no surprise that Australia based company NeuClone is on its way to become a significant player in the biosimilar industry. To date, the company has disclosed information on 6 of its products, 2 of which are being tested in phase 1 clinical trials and an additional 14 are in the works. Although market entry may still be years away, NeuClone is definitely gearing up to show the world what its made of. We spoke with Noelle Sunstrom, the CEO and founder of NeuClone, to discuss the company’s outlook on coming to the US market and how they plan to distinguish themselves from their competitors.

To learn more about NeuClone, visit https://neuclone.com/